HSPs (heat-shock proteins) are molecular chaperones synthesized under stress conditions, and are involved in renal cell survival and matrix remodelling in acute and chronic renal diseases. In the present study, we investigated whether the HSP70 gene polymorphisms affect susceptibility to DN (diabetic nephropathy) in patients with T2DM (Type 2 diabetes mellitus). The study group consisted of 452 patients with nephropathy. Two control subgroups involved 340 healthy individuals and 132 patients with T2DM lasting 10 years who were free of nephropathy. Subjects were genotyped for the HSP70-1 + 190 G/C and − 110 A/C, HSP70-2 + 1267 A/G and HSP70-hom + 2437 T/C polymorphisms by PCR, followed by digestion with restriction endonucleases. There were no statistically significant differences in genotype distribution between patients with T2DM with DN and controls for the HSP70-hom polymorphism. Significant differences were observed for HSP70-1 and HSP70-2 polymorphisms. CC homozygotes of the − 110 and + 190 HSP70-1 polymorphisms were more frequent in patients with T2DM with DN compared with healthy controls (22 compared with 6 % and 15 compared with 6.5 % respectively; P < 0.01). The OR (odds ratio) for the risk allele was 2.17 [95 % CI (confidence interval), 1.73-2.72] for the − 110 A/C and 1.74 (95 % CI, 1.40-2.15) for + 190 G/C polymorphisms. A strong association with DN was found for the + 1267 HSP70-2 polymorphism. The GG genotype and the G allele were associated with DN, with the OR for the G allele being 4.77 (95 % CI, 3.81-5.96). All GG homozygotes in the patient group had higher LDL (low-density lipoprotein)-cholesterol levels than AA homozygotes (P < 0.01), suggesting that the observed effect might be associated with this cardiovascular risk factor. These patients progressed faster to end-stage renal failure than those with other genotypes. In conclusion, our results indicate that the HSP70-1 and HSP70-2 polymorphisms are associated with renal complications in T2DM and may be useful in identifying patients with increased risk of DN.
INTRODUCTION
Diabetic microvascular complications are the major cause of morbidity and premature mortality in T2DM (Type and retinopathy [5] [6] [7] . Numerous polymorphisms in the candidate genes have been investigated in relation to diabetic complications [6] .
HSPs (heat-shock proteins) are molecular chaperones synthesized under stress conditions, and they are induced by denatured proteins during heat shock, ischaemia and other cellular stresses. HSPs are important in physiological and pathological processes and are highly active within the immune system [8] . They help in restoring protein homoeostasis and assist in cellular recovery from stress by repairing damaged proteins through refolding or by degrading them [9] . Oxidant stress plays an important role in renal diseases [10] . Previous studies have documented the crucial role of HSPs in renal cell survival and matrix remodelling in several acute and chronic renal diseases [11] . HSPs have also been reported to be involved in diabetes through their effect on insulin sensitivity [8] .
The HSP70 (70 kDa HSP) family is the most abundant in eukaryotic cells and is essential for cell survival under stress conditions [12] . In humans, three genes encoding members of the HSP70 class are mapped within the MHC class III region (6p21.3): HSP70-1 (HSPA1A), HSP70-2 (HSPA1B) and HSP70-hom (HSPA1L). HSP70-1 and HSP70-2 encode an identical heat-inducible protein HSP70 but differ in their regulatory domains, whereas HSP70-hom encodes a non-heat-inducible form [13] . These genes are polymorphic, with some variants potentially accounting for a change in function and susceptibility to stress tolerance [14, 15] . HSP70 gene polymorphisms were found to be risk factors in several human disorders [15] [16] [17] [18] , and they might play an important role in susceptibility to and/or progression of DN.
To address this possibility, in the present study we investigated the potential involvement of gene variants of HSP70-1, HSP70-2 and HSP70-hom in DN in patients with T2DM.
MATERIALS AND METHODS

Study participants
The study population consisted of 452 unrelated patients with T2DM with DN, 132 patients with a duration of T2DM of 10 or more years, but free of DN (30 % of those had retinopathy) and 340 healthy individuals. All subjects were Caucasians of Polish origin. DN status was determined on the basis of questionnaires, medical files and laboratory data. The AER (albumin excretion rate) was determined in three 24-h urine collections performed at least 1 month apart. DN was diagnosed clinically when the patient had persistent albuminuria 300 mg/24 h in at least two consecutive determinations, in the absence of haematuria or infection. Repeated measurements of the ACR (albumin/creatinine ratio) were performed. Overt proteinuria was defined as an ACR > 28.2 mg/g in men and > 40.2 mg/g in women.
In addition, the patients had no clinical, laboratory or radiological findings indicating any secondary form of nephropathy. All patients with DN were undergoing maintenance dialysis. The mean duration of diabetes was 13.6 (range 9-26) years. The patient subgroup without DN consisted of subjects who had a duration of diabetes of 10 years and an ACR < 1.9 mg/g in men or < 2.8 mg/g in women in at least two determinations. All patients with microalbuminuria were excluded from the study. In the patient group, 392 individuals (67 %) were hypertensive [SBP (systolic blood pressure) > 140 mmHg and DBP (diastolic blood pressure) > 90 mmHg] and were receiving antihypertensive treatment. A total of 72 % of patients with DN were also diagnosed with retinopathy. A positive family history of diabetes in first-degree relatives was reported by 140 patients (24 %).
Control subjects (n = 340) were healthy volunteers (mostly blood donors and hospital staff) with no history of diabetes and renal or cardiovascular disease. Urine analysis was performed in all subjects. Over 40 % of control subjects had an oral glucose tolerance test performed.
Written informed consent was obtained from all subjects enrolled in the study in accordance with principles of the Declaration of Helsinki. The protocol of the study was approved by the institutional Ethics Committee.
Determination of HSP70 genotypes
Genomic DNA was extracted from peripheral blood leucocytes using the method described by Madisen et al. [19] , with minor modifications. Genotypes for HSP70-1, HSP70-2 and HSP70-hom polymorphisms were determined using a PCR-RFLP (restriction-fragmentlength polymorphism) method (Table 1) . Amplified PCR fragments were digested overnight with appropriate restriction endonucleases (Fermentas) and separated on 2 % (w/v) agarose gels.
Statistical analysis
Statistical calculations were performed using SPSS 9.0 for Windows. Normally distributed data are presented as means + − S.D. The Hardy-Weinberg equilibrium was tested with the χ 2 test. Genotype distribution and allele frequencies were compared between groups using a χ 2 test of independence with 2 × 2 contingency and z statistics. A Student's t test and Mann-Whitney U test were used to determine statistical significance. Where appropriate, the ORs (odds ratios) with 95 % CIs (confidence intervals) were calculated. A two-tailed type I error rate of 5 % was considered statistically significant. Multivariate logistic regression with two-way analysis was performed for analysis of independent risk factors for DN. Power calculations were done using an online available power calculator (http://calculators.stat.ucla.edu). 
RESULTS
The demographic and clinical profiles of patients and healthy controls studied are shown in Table 2 . No statistically significant differences in the clinical characteristics were observed between patients with and without DN. The gender distribution was similar in both diabetic and healthy control groups. All patients and control subjects were genotyped for the HSP70-1 − 110 A/C and + 190 G/C polymorphisms, the HSP70-2 + 1267 A/G polymorphism and the HSP70-hom + 2437 T/C polymorphism.
HSP70-1 gene polymorphisms
The frequency of genotypes for HSP70-1 gene polymorphisms did not deviate significantly from the HardyWeinberg equilibrium. The distribution of the genotypes and alleles of the − 110 A/C and + 190 G/C polymorphisms in patients and controls is shown in Table 3 . For both polymorphic sites, significant differences in genotype distribution between patients with T2DM with The risk of DN related to the C allele of the − 110 A/C polymorphism and the C allele of the + 190 G/C polymorphism remained unchanged after multivariate logistic regression analysis with age, gender, diabetes duration, HbA 1c (glycated haemoglobin) and hypertension as covariates.
HSP70-2 + 1267 A/G polymorphism
The distribution of genotypes and alleles of this polymorphism is shown in Table 5 . The GG genotype and G allele were significantly associated with DN, with an OR All GG homozygotes in the patient group had higher total cholesterol and LDL (low-density lipoprotein)-cholesterol levels than AA homozygotes (236 + − 41 compared with 189 + − 33 mg/dl and 141 + − 25 compared with 117 + − 29 mg/dl respectively; P < 0.01). This suggests that the observed effect of the + 1267 A/G polymorphism might be associated with cardiovascular risk factors.
We have preliminary observations suggesting some effect of the GG homozygosity on the progression of DN to ESRD (end-stage renal disease). The mean time from the diagnosis of DN to ESRD was 4.4 years for the GG homozygotes compared with 8.7 years for the AA homozygotes (P < 0.001). These effects were not observed for the HSP70-1 gene polymorphisms. This observation will be a subject of our future studies.
HSP70-hom + 2437 T/C polymorphism
There was no statistically significant difference in the genotype distribution between patients with T2DM with DN, patients with T2DM without DN and healthy controls (results not shown).
DISCUSSION
HSPs synthesized under stress conditions are involved in several human diseases. There are studies suggesting an important role of HSP70 proteins in T1DM (Type 1 diabetes mellitus) with DN [20] , T2DM [21] and vascular events in patients with T2DM [22] .
To our knowledge, the present study is the first showing a significant association between HSP70 gene polymorphisms and DN in patients with T2DM. We hypothesized that genetic variations in the HSP70 genes might affect the risk of microvascular complications in T2DM. A total of 252 patients with T2DM were genotyped for the HSP70-1, HSP70-2 and HSP-hom polymorphisms. The results show that HSP70-1 gene polymorphisms at positions − 110 and + 190 and the HSP70-2 gene variant at position + 1267, a silent change in the coding region, are associated with DN in patients with T2DM. It should be mentioned that all patients with T2DM with DN in our present study had ESRD due to DN, so we did not study the relationship between genotype and the stage of nephropathy.
Variations − 110 A/C and + 190 G/C are in the 5 flanking and non-coding regions of the HSP70-1 gene and have been shown previously to be associated with Parkinson's disease [15] , coeliac disease [23] and autoimmune thyroid disease [24] . The − 110 A/C polymorphism is located 3 bp upstream of the heat-shock element essential for the heat inducibility of the HSP70-1 gene. It also lies within the five consecutive regulatory elements involved in the binding of regulatory proteins [25] . It is thus possible that − 110 A/C alters the regulation of the HSP70-1 gene.
Both variations in the HSP70-1 gene, − 110 A/C and + 190 G/C, appear to be genetic risk factors for DN, with similar ORs for the minor allele (2.17 and 1.74 respectively). In fact, a strong linkage disequilibrium was reported between − 110 A/C and + 190 G/C and between HSP70-1 − 110 A/C and HSP70-2 + 1267 A/G [15, 26] .
The two polymorphisms in the HSP70 genes, HSP70-1 − 110 A/C and HSP70-2 + 1276, found in our present study to be associated with DN, may be related to the disease through similar mechanisms. It was reported previously that the HSP70-1 − 110C and HSP70-2 + 1267G alleles are strongly non-randomly associated with each other [26] . These two HSP70 genes share a similar heat-shock element, which suggests their similar affinities for heat-shock factor. The HSP70-1 and HSP70-2 genes also share the same transcriptional start site [13] . The sequence differences in 5 flanking regions suggest that these genes may be differentially regulated in response to stress factors other than heat shock. Pociot et al. [27] reported the association between variable HSP70-2 mRNA expression and the + 1267 polymorphism. In subjects with a homozygous GG genotype, a decrease in mRNA expression might occur and the cell response to stress would be impaired, leading to the intracellular accumulation of denaturalized proteins or peptide-transporting defects. Sequence variations that result in altered expression or protein activity could determine the susceptibility to disease.
It is possible that the HSP70-2 polymorphism is not involved causally in contributing to DN, but is in a linkage disequilibrium with some neighbouring gene on chromosome 6p.
In our group of patients with T2DM and DN, all GG homozygotes of the HSP70-2 + 1267 polymorphism had higher total cholesterol and LDL-cholesterol levels than AA homozygotes. Thus the observed effect of the polymorphism might be associated with an increased risk of cardiovascular disease. This is in agreement with a study by Giacconi et al. [22] , in which the authors demonstrated that total cholesterol and LDL-cholesterol concentrations were significantly higher in B + (presence of a G allele) than in B− patients with T2DM and atherosclerosis.
The HSP70-hom + 2437 T/C polymorphism (Met → Thr amino acid substitution at position 493) was reported to be associated with spondyloarthropathies [16] and sarcoidosis [17] . It was also found to affect T1DM [27] . It is thought that this substitution may be associated with variations in the peptide-binding specificity of different HSP70-hom haplotypes. In our present study, this polymorphism did not have any effect on susceptibility to DN. In another study, the HSP70-hom + 2437 T/C polymorphism was investigated along with HSP70-1 and HSP70-2 gene polymorphisms, but was found not to be involved in the susceptibility to Parkinson's disease [15] .
The associations between the HSP70 gene polymorphisms and DN, shown in our present study, are not observed for diabetes itself.
The strengths of our present study are that all of the patients and controls are of the same ethnic origin. Furthermore, all of the subjects were examined in a standardized manner with well-defined diagnostic criteria. All genotyping was performed in a blinded manner with respect to case-control status; however, the genetic heterogeneity and small effects of some diseaseassociated alleles make association studies difficult in multifactorial diseases with complex phenotypes. The occurrence of diabetes and/or its complications depends on the interaction among the presence of different risk alleles, environmental factors and lifestyle. The influence of any single polymorphism is rather small and an interactive effect of several factors may lead to an underestimation or an overestimation of a role of a given polymorphism in determining the phenotype.
In conclusion, our present results suggest that the HSP70-1 and HSP70-2 gene polymorphisms are associated with a predisposition to DN in patients with T2DM, at least in this Polish population. This is a novel observation which needs to be confirmed in additional studies in larger numbers of patients and control subjects. In addition, functional studies are needed to elucidate the involvement of HSP70 genes in diabetic microvascular complications. If the associations observed in the present study are confirmed, HSP70 gene polymorphisms may be useful in identifying patients with diabetes with an increased risk of DN.
